Scotland backs UCB's Zilbrysq while NICE appraisal in England remains unresolved
- nuaxia
- il y a 2 jours
- 2 min de lecture
The differing reimbursement positions highlight how health technology assessment decisions can diverge across UK nations, affecting the timing of patient access to new medicines.
The Scottish Medicines Consortium (SMC) has accepted UCB's Zilbrysq (zilucoplan) for restricted use within NHS Scotland to treat adults with anti-acetylcholine receptor (AChR) antibody-positive generalised myasthenia gravis following a successful resubmission.
In contrast, NICE has not yet issued final guidance for NHS England, leaving reimbursement decisions unresolved while its technology appraisal continues.
Field | Content |
Alert Type | Industry Update |
Topic | Health technology assessment (HTA) and market access |
Organisation(s) | Scottish Medicines Consortium (SMC); National Institute for Health and Care Excellence (NICE); UCB |
Affected Stakeholders | Patients with generalised myasthenia gravis, neurologists, NHS Scotland, NHS England, UCB and healthcare commissioners |
Therapy Area(s) | Neurology; Generalised myasthenia gravis |
Geography | United Kingdom (Scotland and England) |
What Happened | The SMC accepted zilucoplan (Zilbrysq) for restricted use within NHS Scotland following a resubmission under its orphan equivalent medicine process, enabling access for eligible adults with anti-AChR antibody-positive generalised myasthenia gravis. At the same time, NICE has not completed its appraisal for NHS England, with final guidance still pending following further committee consideration, meaning routine NHS funding in England has not yet been confirmed. |
Why It Matters | The differing decisions demonstrate that market access timelines can vary across UK healthcare systems even after regulatory approval. For manufacturers, clinicians and patients, reimbursement outcomes from HTA bodies remain a critical determinant of when new medicines become routinely available. |
Supporting Context | Zilbrysq is indicated as an add-on to standard therapy for adults with anti-AChR antibody-positive generalised myasthenia gravis. The SMC previously did not recommend the medicine before accepting it following a resubmission, while NICE's appraisal has undergone multiple rounds of consultation and review. |
Who Is Most Affected | Neurologists treating generalised myasthenia gravis and eligible patients in Scotland are most immediately affected through NHS access, while clinicians and patients in England continue to await NICE's final funding recommendation. |
Industry Impact | The contrasting HTA outcomes reinforce the importance of country-specific evidence generation, pricing strategies and health economic submissions when seeking reimbursement across the UK. Future access in England will depend on NICE's final appraisal and any associated commercial arrangements. |
Key Takeaway | The latest decisions illustrate how reimbursement for the same medicine can diverge across UK HTA bodies, influencing when patients gain routine NHS access. |
What to Watch | NICE's final guidance for zilucoplan in England, expected following completion of its ongoing technology appraisal, and whether reimbursement becomes aligned across the UK. |
Primary Source | |
Relevant Date | 10 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Commentaires